Global Health R&D at BARDA

What does BARDA do for global health R&D?
The Biomedical Advanced Research and Development Authority (BARDA), within the Department of Health and Human Services, supports the advanced development of vaccines, drugs, and other medical countermeasures to protect Americans against threats to public health, including emerging infectious diseases and antimicrobial resistance.

Why is BARDA’s role in global health R&D important?
BARDA works with industry to bridge the “valley of death” between basic research and product development. Through unique contracting and incentive mechanisms, BARDA’s partnerships ensure promising research is translated into urgently-needed medical products, even if there is limited commercial incentive for the private sector.

Impact of Investment

<table>
<thead>
<tr>
<th>Health Area focus</th>
<th>AMR</th>
<th>Ebola/ VHF s</th>
<th>Other emerging diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zika</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pandemic Influenza</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BARDA R&D success stories: Saving lives, saving money

**AMR**
Supporting antibiotic development, through the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, with the goal of building a portfolio of more than 20 potential new antibiotics.

Development of a genetic sequencing platform to detect pathogens in patient samples in hours, rather than days, and anticipate antimicrobial resistance (AMR) patterns, enabling clinicians to more effectively treat drug-resistant infections.

**ZIKA**
Partnering with biotech and pharmaceutical companies to develop several Zika vaccine candidates and improved diagnostic tools and technologies to screen blood supplies for the virus.

**INFLUENZA**
Strengthening manufacturing capacity in low- and middle-income countries to enable rapid production of seasonal and pandemic influenza vaccines.

**EBOLA**
Partnering with biotech and pharmaceutical companies to develop several Ebola vaccine candidates, point-of-care diagnostic tools, and experimental treatments.

Abbreviations:
AHFs: viral hemorrhagic fevers, AMR: antimicrobial resistance.